Later on, the same research team administered six courses of HHT to 90 CML patients at early CP (< 1 year from diagnosis); they were later switched to maintenance therapy with IFN-α. The gene discussed is IFNA1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.